Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

At several time points, including weeks 12, 24, and 36, a trend toward improvement in epratuzumab‐treated patients over placebo was seen, with nominally significant differences between the placebo + standard therapy group and the epratuzumab + standard therapy treatment groups (i.e., P < 0.05 versus placebo, without adjustment for multiple comparisons).

also in 7,732 other papers